We are a precision genetic medicines company committed to developing curative
therapeutics for patients using our proprietary, comprehensive
metagenomics-derived genome editing toolbox. Genetic diseases are caused by a
diverse set of mutations that have been largely inaccessible by genome
engineering approaches to date. Genetic mutations are seen in a variety of
forms, including deletions, insertions, single-base-pair changes and sequence
repeats, and are found throughout the genome and across a variety of different
cell types, tissues, and organ systems. Additionally, many diseases lack a
genetic origin but have the potential to be effectively and permanently
addressed through genome editing. We are harnessing the power of metagenomics,
the study of genetic material recovered from the natural environment, to unlock
four billion years of microbial evolution to discover and develop a suite of
novel editing tools capable of correcting any type of genetic mutation found
anywhere in the genome. Our comprehensive genome editing toolbox includes
programmable nucleases, base editors, and RNA and DNA-mediated integration
systems (including prime editing systems and clustered regularly interspaced
short palindromic repeat (“CRISPR”)-associated transposases (“CASTs”)). We
believe our diverse and modular toolbox positions us to access the entire genome
and select the optimal tool to unlock the full potential of genome editing for
patients.
Lead Underwriter
BMO Capital Markets Corp,Cowen and Company, LLC,J.P. Morgan Securities LLC,Jefferies LLC,Wells Fargo Securities, LLC
